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Abstract
Long chain n-3 PUFA have been shown to have chemopreventive properties against breast cancer through various
mechanisms. One pathway, studied in human breast cancer cell lines, involves upregulation of the proteoglycan, syndecan-
1 (SDC-1) by n-3 PUFA-enriched LDL. Using Fat-1 mice that are able to convert n-6 to n-3 PUFA, we tested whether SDC-1
level in vivo is elevated in mammary glands due to endogenously synthesized rather than LDL-derived n-3 PUFA. Female
Fat-1 and wild type (wt) mice were fed an n-6 PUFA- enriched diet for 7 weeks. Fatty acid analysis of plasma lipoproteins
showed that total n-6 PUFA reflected dietary intake similarly in both genotypes (VLDL, 36.262.2 and 40.963.9; LDL,
49.063.3 and 48.162.0; HDL, 54.661.2 and 58.261.3, mean 6 SEM percent of total fatty acids for Fat-1 and wt animals
respectively). Lipoprotein percent n-3 PUFA was also similar between groups. However, phospholipids and triglycerides
extracted from mammary and liver tissues demonstrated significantly higher n-3 PUFA and a corresponding decrease in the
ratio n-6/n-3 PUFA in Fat-1 compared to wt mice. This was accompanied by higher SDC-1 in mammary glands and livers of
Fat-1 mice, thus demonstrating that endogenously synthesized n-3 PUFA may upregulate SDC-1 in the presence of high
dietary n-6 PUFA.
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Introduction
A large body of evidence now points to protective role against
breast cancer for the long chain marine n-3 polyunsaturated fatty
acids (PUFA), eicosapentaenoic acid (EPA, 20:5n-3) and docosa-
hexaenoic acid (DHA, 22:6n-3). Due to a lack of the necessary
desaturases,theseessential fattyacidscannotbe synthesizedde novo
by mammals and must be obtained from diet. Human population
studies have demonstrated an inverse relationship between breast
cancer incidence and calories from fish oil [1,2]. In addition, data
from 20 countries not only identified a negative relationship with
fish oil consumption, but also a positive correlation between breast
cancer and intake of saturated and n-6 polyunsaturated fat [3].
Animalstudieshaveprovidedstrongsupportforaroleofdietaryfats
in breast cancer. In chemical carcinogen-induced breast cancer in
rats [4,5,6,7,8] and human cancer cell xenografts in nude mice
[9,10,11], tumor growth rate, size and metastases were all
suppressed by n-3 PUFA and promoted by n-6 PUFA diets. In
more recent studies with HER-2/neu transgenic mouse models of
spontaneous breast cancer, a fish oil diet compared to a corn oil diet
increased the latency time to tumor development, reduced the
number of tumors and was associated with a lower grade of
mammary gland histopathology [12,13].
As reviewed [14,15], insights into the mechanisms responsible
for the anti-breast cancer properties of n-3 PUFA have been
provided largely by in vitro investigations with human breast
cancer cell lines. Of several mechanisms proposed, the most
frequently cited for their anti-cancer activity is the ability of n-3
PUFA to block the metabolism of the n-6 PUFA, arachidonic acid
(AA) and linoleic acid (LA) into compounds that promote the
malignant phenotype of cancer cells [14,15,16,17,18,19]. This
may involve differential activation of the nuclear receptor, PPARc
and/or differential regulation of intracellular signaling pathways
by n-3 and n-6 PUFA. Our previous in vitro studies have defined a
novel pathway whereby n-3 PUFA-enriched LDL inhibits human
breast cancer cell growth: the n-3 PUFA, DHA activates PPARc
which results in transcriptional up-regulation of the Sdc-1 target
gene and the syndecan-1 (SDC-1) protein induces apoptosis
[20,21,22]. SDC-1 is the primary cell surface proteoglycan of
epithelial cells and has been implicated in a number of regulatory
processes in tumorigenesis including adhesion [23,24,25,26],
sequestration and storage of growth factors for which it may serve
as a co-receptor [27,28,29], invasion [30,31] and induction of
apoptosis [22,32]. Its in vivo regulation by n-3 PUFA may
therefore have a profound effect on breast cancer growth and
progression.
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20502The Fat-1 mouse was engineered by Kang et al [33] to express
the fat-1 gene from Caenorhabditis elegans. This encodes an n-3
desaturase that can convert n-6 to n-3 fatty acids to result in
increased levels of n-3 PUFA in all major tissues. Previous reports
have not addressed effects of the n-3 PUFA enrichment on genes
that are regulated by these fatty acids. The use of this model
allowed us to determine that SDC-1 can be upregulated in vivo by
tissue n-3 PUFA in the absence of n-3 PUFA-enriched
lipoproteins.
Materials and Methods
Mice and diets
Animal care was conducted in compliance with the state and
federal Animal Welfare Acts and standards and policies of the
Department of Health and Human Services. The protocol (A09–
131) was approved by the Wake Forest University Animal Care
and Use Committee. Fat-1 transgenic mice were generously
supplied by Dr. Jing X. Kang, Department of Medicine,
Massachusetts General Hospital and Harvard Medical School,
Boston, Massachusetts. The genetic groups (Fat-1 and wild type
littermates) consisted of 5 female animals. All animals were housed
in an isolated environment in barrier cages and a fed specific diet
for 7 weeks after weaning. Diets were prepared by the custom
animal diet laboratory of the Animal Resources Program at Wake
Forest University and contained 397 kcal/100g; 30% of energy
was from fat, 50% from carbohydrates and 30% from proteins.
The fatty acid content was 30% saturated (16:0+18:0), 26%
monounsaturated (18:1) and 43% n-6 polyunsaturated (18:2).
Detailed diet composition has been previously described [34]. At
termination, mice were fasted for 4 h and then euthanized. A
blood sample was immediately drawn via heart puncture.
Plasma lipids and lipoproteins
The terminal blood samples were placed into tubes containing
a protease inhibitor cocktail (Sigma) dissolved in 5% EDTA, 5%
NaN3. Plasma was separated by centrifugation at 12,500 g for
15 min, 4uC. Lipoproteins (VLDL, LDL, and HDL) were
isolated by gel filtration chromatography of whole plasma
injected onto a Superose 6 10/300 GL column (GE Healthcare)
and lipoproteins eluted with 0.9% saline, 0.01% EDTA and
0.01% NaN3 at 0.4 ml/min. The HPLC chromatography system
used was a LaChrom Elite (Hitachi High Technologies)
consisting of an L-2200 Autosampler with Peltier cooling, an
L-2420 UV-VIS Detector, and an L-2100 SMASH pump. Fatty
acid distributions in whole plasma and isolated lipoproteins were
determined by gas chromatography following methylation of the
fatty acid moieties. Fatty acid methyl esters were separated and
quantified by gas chromatography (GC) on a CP Select for
FAME capillary column (100 m60.25 mm id, Varian) installed
in an Agilent 6890N gas chromatograph with a programmable
cool on-column capillary inlet, flame ionization detector (FID),
and Agilent 7683B autosampler/injector. Chromatographic data
collection and analysis was via Chrom Perfect
TM Spirit
Chromatography Data System (version 5.0) in Microsoft
Windows XP Pro. The chromatographic conditions were: H2
carrier gas, 20 psi head pressure, 1.25 ml/min at 90uC; N2
make-up gas, 23 ml/min; inlet temperature at 3uC above the
oven temperature; and FID at 230uC. The oven temperature
was programmed to begin at 90uC and hold for 0.5 min,
increase at 10uCp e rm i nt o1 5 0 uC, increase at 2.5uC per min to
200uC, increase at 1.5uC per min to the final temperature,
220uC, and hold at 220uCf o r2 0m i n .
Mammary gland and liver lipid analysis
At necropsy, mammary glands and livers were dissected,
washed twice with balanced salt solution (BSS [137 mM NaCl,
2.7 mM KCl, 1.45 mM KH2PO4, 20.3 mM Na2HPO4, pH 7.4]),
and divided into sections for lipid, protein, mRNA and
immunohistochemical analyses. Lipids were extracted with
chloroform-methanol and lipid classes were separated by thin
layer chromatography. Bands corresponding to triglyceride (TG)
and phospholipid (PL) were scraped and methyl esters were made
by addition of NaOH in methanol, followed by boron trifluoride in
methanol. Fatty acids were quantified by gas chromatography as
above.
Determination of cholesterol, triglyceride and
phospholipid content of tissues
Aliquots of chloroform extracts were evaporated to dryness
under nitrogen, and exchanged into aqueous solution by addition
of 2 ml of 1% Triton X -100 in chloroform, re-evaporation and
solubilization of the detergent residue in 0.5 ml dH2O. Total
cholesterol (TC) and TG were measured using standard enzymatic
procedures [35]. PL was measured in a separate aliquot as
inorganic phosphorous [36].
Western blot assay
Mouse mammary and liver tissues were homogenized and lysed
in ice-cold lysis buffer (25 mM Tris-HCl, 150 mM NaCl, 1%
Triton X-100, 0.1 mg/ml PMSF) with 16 Proteinase and
16Phosphatase inhibitors (Roche Applied Science). For the
analysis of SDC-1 protein, lysates were dialyzed against hepar-
itinase buffer (50 mM HEPES, 50 mM NaOAc, 150 mM NaCl,
5 mM CaCl2) for 24 h at 4uC and then digested by chondroitinase
ABC (Seikagaku, America) and heparinase III (Sigma-Aldrich
Company, Allentown, PA) at 37uC overnight. Protein extracts
were prepared for Western blot analysis as described earlier using
indicated antibodies [37]. Band densities on photographic films
were analyzed using Image J 1.37v (NIH).
Quantification of mRNA levels
Total mRNA was extracted from mammary glands and liver of
five wild type and Fat-1 mice with RNeasyH Protect Mini Kit (Cat.
No. 74124, QIAGEN, Maryland). Quantitative real-time PCR
(RT-PCR) was performed as described [21,22]. Amplification
reactions were performed in triplicate in Applied Biosystems 7500
Real-Time PCR System. The primers used for mouse SDC-1 were
59-tggagaacaagacttcacctttg-39 (forward) and 59-ctcccagcacttccttcct-
39 (reverse), mouse SDC-4 were 59-atggacctggagccagctcacccccaa-
39 (forward) and 59-tcatgcgtagaactcattggtggg-39 (reverse), mouse
perlecan were 59-caagcagtttctgggcaacaaggt-39 (forward) and 59-
acccacgaggatcacatctggttt-39 (reverse), mouse versican were 59-
tggatcatctggatggcgatgtgt-39 (forward) and 59-caaagccatttctc-
caagctgcct-39 (reverse), mouse decorin were 59-acctctcgtgaagttg-
gaaaggct-39 (forward) and 59-tccgcagcttggtgatctcattct-39 (reverse),
and mouse biglycan were 59-caacaacatcaccaaggtgggcat-39 (for-
ward) and 59-tggcaaccactgcctctacttctt-39 (reverse). Primers for
mouse peptidylprolylisomerase B (PPIB) housekeeping gene were
59-gcccaaagtcaccgtcaa (forward) and 59-tccgaagagaccaaagatcac
(reverse). Care was taken to design the primers so as to minimize
amplification from any contaminating genomic DNA. Melt curve
analyses performed at the end of the real-time PCR reproducibly
show a single peak. SDC-1, SDC-4, perlecan, versican, decorin
and biglycan data were normalized to the housekeeping control
PPIB.
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Mammary tissues were fixed in buffered formalin at 4uC,
embedded in paraffin, sectioned and deparaffinized. Immuno-
staining was conducted using a rabbit polyclonal antibody raised
against a recombinant protein corresponding to amino acids 82-
256 of human SDC-1 (H174 from Santa Cruz Biotechnology,
Santa Cruz, CA) and the DAKO EnVion +system peroxidase 3,
39-diaminobenzidine (DAB) kit according to the manufacturer’s
instructions.
Statistical analyses
Data are expressed as mean 6 SD or SEM. Results were
analyzed by Student’s t test and differences were considered
significant at P,0.05.
Results
Plasma lipoproteins of Fat-1 mice fed an n-6 PUFA diet
are deficient in n-3 PUFA
The effects of the n-6 PUFA enriched diet on plasma
lipoproteins are shown in Fig. 1. When Fat-1 and wt mice were
fed a commercial chow control diet (n-6 to n-3 ratio, approxi-
mately 5-8 to 1) significantly higher n-3 PUFA were measured in
the whole plasma of Fat-1 compared to wt mice (Fig. 1A). This was
presumably due in part to elevated n-3 PUFA free fatty acids
because percent n-3 PUFA in isolated lipoproteins was similar
between Fat-1 and wt mice. In agreement with these data, n-6/n-3
ratios in Fat-1 compared to wt mice were significantly lower in
whole plasma only and not in isolated lipoproteins (Fig. 1B). Seven
weeks of the n-6 PUFA diet (n-6 to n-3 ratio of 40) resulted in an
elevation in plasma n-6 PUFA with a corresponding decrease in n-
3 PUFA for both genotypes (Fig. 1C versus 1A). A similar
reduction in percent n-3 PUFA for Fat-1 and wt mice was
observed for all lipoprotein species. This resulted in a marked
increase in the n-6/n-3 PUFA ratios of whole plasma and isolated
lipoproteins with no differences in response between the genotypes
(Fig. 1D versus 1B). Thus the lipoproteins directly reflected dietary
PUFA intake with little influence of the fat-1 transgene.
Mammary tissue and liver lipids of Fat-1 mice fed an n-6
PUFA diet are enriched in n-3 PUFA. No differences were
observed in the percent distribution of mammary tissue lipids
which was 98.760.1 and 98.960.2 in TG, 1.060.1 and 0.860.4
in PL, 0.360.03 and 0.260.08 in TC, mean 6 SEM for Fat-1 and
wt respectively. These lipid classes were separated by TLC and
analyzed for fatty acid content. The percent fatty acid composition
of mammary tissue PL is shown in Table 1 and of TG in Table 2.
For both of these lipids, there was no difference between Fat-1 and
wt mice for total saturated and monounsaturated fatty acids.
Figure 1. Fatty acid composition of whole plasma (WP) and lipoproteins of Fat-1 and wild type (wt) mice fed a chow control (A, B)
and n-6 PUFA-enriched diet (C, D). Lipoproteins were isolated by gel filtration chromatography and fatty acids were measured as methyl esters
by gas chromatography. Bars represent the means 6 SEM of A and C, total n-3 PUFA (eicosapentaenoic acid, 20:5; docosapentaenoic acid, 22:5;
docosahexaenoic acid, 22:6); B and D, ratio of n-6 PUFA (linoleic acid, 18:2+ arachidonic acid, 20:4) to n-3 PUFA . * P,0.05 Fat-1 versus wt by Student’s
t test.
doi:10.1371/journal.pone.0020502.g001
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(DPAn-3 , 22:5), were significantly higher in PL of Fat-1 compared
to wt mice and this resulted in a 44% lower n-6/n-3 ratio in Fat-1
relative to wt (Table 1). The n-6/n-3 ratio was likewise
significantly lower in the TG fraction from Fat-1 relative to wt
mice (Table 2). In TG however, the higher n-3 PUFA in Fat-1
mice was due to an increase in DHA (22:6), as well as in DPAn-3.
In liver tissues, in which the n-6/n-3 ratio in PL was 37% lower
in Fat-1 than wt, DHA was the only detectable n-3 PUFA that was
significantly elevated in Fat-1 compared to wt (Table 3). In liver
TG, a 33% lower n-6/n-3 ratio (p=0.06) was measured, mainly as
a result of higher DPAn-3 in Fat-1 compared to wt tissue (Table 4).
SDC-1 mRNA and protein is elevated in Fat-1 compared to
wt mice. SDC-1 is up-regulated when mammary cells are treated
in vitro with n-3 PUFA [20,22]. We investigated whether the
modest increase in n-3 PUFA measured in the mammary tissues of
the Fat-1 mice was sufficient to modify the expression of SDC-1 in
vivo. As shown in Fig. 2A, mRNA for SDC-1 was 50% higher in
mammary tissue of Fat-1 compared to wt mice. This effect was
specific for SDC-1 since expression of the other proteoglycans,
SDC-4, perlecan, decorin and biglycan were similar between Fat-1
and wt tissues (Fig. 2A). It is of interest to note that expression of the
chondroitin sulfate proteoglycan, versican, which is generally
thought to have a tumor-promoting effect, trended lower
(p=0.057) in the n-3 PUFA-enriched Fat-1 tissues. No previous
studies have reported regulation of versican by n-3 PUFA. To
determine whether SDC-1 expression was elevated in tissues other
than mammaryglandof Fat-1mice, weexamined liverwhereSDC-
1 is known to function in the clearance of triglyceride-rich
lipoprotein remnants [38]. As shown in Fig. 2B, SDC-1 mRNA
was . two-fold higherin the livers of Fat-1 compared to wt animals.
To confirm that the increased SDC-1 mRNA in Fat-1 tissues was
translated into increased protein, Western analysis of tissue protein
Table 1. Mouse mammary gland phospholipid fatty acid
composition.
Fatty acid Wild type Fat-1
14:0 0.860.1 0.560.4
a
16:0 21.961.5 21.961.2
16:1n-7 2.060.2 1.860.4
18:0 20.561.0 19.860.9
18:1n-9 14.561.0 15.863.1
18:2n-6 15.961.4 14.462.5
18:3n-3 0.1
b 0.1
c
20:3n-6 0.860.01 0.760.05
20:4n-6 14.260.6 13.861.6
20:5n-3 0.160.05 0.360.03*
22:2n-6 0.260.05 0.260.06
22:5n-6 2.460.5 2.460.9
22:5n-3 0.360.04 0.860.1*
22:6n-3 1.660.5 2.561.7
Sum n-6 PUFA 32.961.6 31.563.2
Sum n-3 PUFA 2.060.5 3.661.7
n-6/n-3 ratio 17.663.9 9.862.9*
adata are mean 6 SD of percent total FA.
bdetected in one sample only.
cdetected in two samples only.
*Significantly different (P,0.05) between Fat-1 and wild type mice.
doi:10.1371/journal.pone.0020502.t001
Table 2. Mouse mammary gland triglyceride fatty acid
composition.
Fatty acid Wild type Fat-1
14:0 1.360.07 1.460.2
a
16:0 23.361.0 23.162.0
16:1n-7 5.360.7 4.560.7
18:0 2.460.2 2.760.3
18:1n-9 35.560.9 36.460.6
18:2n-6 29.660.9 30.361.3
18:3n-3 0.260.01 0.260.01
20:3n-6 0.260.01 0.260.02
20:4n-6 0.560.04 0.460.04
20:5n-3 0.0260.004 0.0360
b
22:2n-6 0.0560.02 0.0360.01
22:5n-6 0.260.04 0.260.02
22:5n-3 0.0260.005 0.360.004*
22:6n-3 0.0560.01 0.0760.008*
Sum n-6 PUFA 30.561.0 30.861.3
Sum n-3 PUFA 0.260.03 0.360.01*
n-6/n-3 ratio 128.2615.8 107.965.5*
adata are mean 6 SD of percent total FA.
ball samples had same value.
*Significantly different (P,0.05) between Fat-1 and wild type mice.
doi:10.1371/journal.pone.0020502.t002
Table 3. Mouse liver phospholipid fatty acid composition.
Fatty acid Wild type Fat-1
14:0 0.160.01 0.160.02
a
16:0 19.561.8 19.360.9
16:1n-7 0.560.05 0.460.1
18:0 19.661.1 19.961.1
18:1n-9 7.960.6 6.861.0
18:2n-6 14.161.1 14.560.5
18:3n-3 nd nd
20:3n-6 1.460.2 1.160.2
20:4n-6 24.660.9 24.561.2
20:5n-3 nd nd
22:2n-6 nd nd
22:5n-6 4.560.9 3.560.7
22:5n-3 0.1
b 0.260.01
22:6n-3 4.260.8 6.761.2*
Sum n-6 PUFA 44.661.3 43.661.4
Sum n-3 PUFA 4.360.7 6.961.3*
n-6/n-3 ratio 10.661.9 6.761.2*
adata are mean 6 SD of percent total FA.
bone sample only.
nd none detected.
*Significantly different (P,0.05) between Fat-1 and wild type mice.
doi:10.1371/journal.pone.0020502.t003
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mammary tissue (Fig. 2C) and a 50% higher SDC-1 protein in liver
(Fig. 2D) of Fat-1 compared to wt mice. Finally, since whole mount
preparations of mammary glands of Fat-1 mice were previously
shown to display a more differentiated phenotype than wt animals
[39], we examined SDC-1 distribution in the mammary tissues
(Fig. 3).Immunostaining for SDC-1,localized primarilyto epithelial
components, was consistently more intense in Fat-1 than in wt
tissues but no significant morphological differences were observed
between the genotypes.
Discussion
The conclusion from our studies is that endogenously
synthesized n-3 PUFA in mouse mammary gland and liver are
associated with an upregulation of SDC-1 expression in the
absence of n-3 enriched LDL. This conclusion is drawn from the
data showing that as a result of high n-6 PUFA dietary intake, the
lipoproteins in both Fat-1 and wt mice are highly enriched in n-6
PUFA and lack detectable n-3 PUFA. Nevertheless, the mammary
tissue and liver lipids of the Fat-1 group display an elevation in n-3
PUFA compared to wt as a result of the fat-1 transgene. The
increase in n-3 PUFA in these animals was very modest, but it was
sufficient to be associated with increased expression of SDC-1
mRNA and protein. Although we have previously demonstrated
increased expression of SDC-1 in prostate tissues of mice fed an n-
3 PUFA enriched diet [40], the present study is the first time that
this relationship has been investigated in mammary gland and
liver in vivo and in a genetic model of n-3 PUFA regulation.
Table 4. Mouse liver triglyceride fatty acid composition.
Fatty acid Wild type Fat-1
14:0 0.760.5 0.660.3
a
16:0 27.061.5 29.162.3
16:1n-7 3.161.6 1.761.0
18:0 2.060.4 2.560.4
18:1n-9 37.662.9 34.361.1*
18:2n-6 22.062.6 24.062.9
18:3n-3 0.0860.01 0.0860.03
20:3n-6 0.660.2 0.760.2
20:4n-6 1.560.8 1.460.9
20:5n-3 nd nd
22:2n-6 nd nd
22:5n-6 0.560.2 0.860.3
22:5n-3 0.0260.01 0.0760.02*
22:6n-3 0.160.05 0.260.04*
Sum n-6 PUFA 24.663.4 27.462.3
Sum n-3 PUFA 0.1660.06 0.2760.08*
n-6/n-3 ratio 163648 109629
adata are mean 6 SD of percent total FA.
nd none detected.
*Significantly different (P,0.05) between Fat-1 and wild type mice.
doi:10.1371/journal.pone.0020502.t004
Figure 2. Expression of proteoglycans in tissues of Fat-1 and wild type (wt) mice. A. transcript levels of proteoglycans in mammary gland.
B, transcript levels of SDC-1 in liver. Total RNA was isolated from tissues and mRNAs were measured by real-time RT-PCR. Numbers represent the level
of expression relative to that of a housekeeping gene, peptidyl prolyl isomerase B (PPIB) using triplicate samples of each animal (n=5). The
expression of SDC-4 relative to PPIB in mammary tissue was ,0.001 and similar between Fat-1 and wt tissues. C and D. Western analysis using a SDC-
1 core protein-specific antibody of heparinase-treated protein extracts of C, mammary tissues and D, liver. Bars are means 6 SEM (n=5) of SDC-1
protein adjusted to b actin. Insert shows representative samples of wt and Fat-1bands. * P,0.05 Fat-1 versus wt by Student’s t test.
doi:10.1371/journal.pone.0020502.g002
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gene regulation studies by eliminating variations in dietary fatty
acid combinations. Kang et al [33] reported increased n-3 PUFA
in all major tissues of this model including muscle, heart, brain,
liver, kidney, lung, and spleen. Increases in n-3 PUFA reported in
mammary gland by Ma et al [41] and in liver by Kang et al [33]
were higher in Fat-1 mice than those of the present studies. This
may be due to a dampening effect on the desaturase gene by the
higher fat diet used in our studies. Further it was shown that in
brain tissue, DHA levels achieved in this model were similar to
those achieved by fish oil feeding [42]. An anti-tumor role for n-3
PUFA in Fat-1 mice was suggested by studies showing a reduced
colitis-associated colon cancer that was associated with a decreased
inflammatory response [43,44]. In addition, the growth of
implanted B16 human melanoma cells was markedly reduced in
Fat-1 compared to wt mice [45]. Our previous studies have shown
that introduction of the fat-1 gene into a prostate specific Pten
knock-out mouse model of prostate cancer reduced tumor growth
similar to the effect of an n-3 PUFA diet [34]. Whether the
increased n-3 PUFA would protect Fat-1 mice against breast
cancer remains to be studied.
A few in vitro studies have examined biological and biochemical
effects of expression of the fat-1 transgene that result from the
increased n-3 PUFA. In human prostate cancer cell lines
transfected with the fat-1 gene, proliferation was inhibited through
a reduction in GSK-3b phosphorylation and a subsequent
downregulation of b-catenin and cyclin D1[46]. In human lung
cancer cells, the increased n-3 PUFA in fat-1-transfected cells
resulted in reduced invasive properties due to down regulation of
invasion-related genes, MMP-1 and integrin-a2 [47]. The studies
described here present SDC-1 as a new candidate for regulation
by the n-3 PUFA-enriched environment produced by the fat-1
Figure 3. Immunostaining of SDC-1 in mammary glands of Fat-1 and wild type mice. Mammary glands from wt (A) and Fat-1 (B) mice
were fixed, sectioned and immunostained with antibody H-174 raised against a recombinant protein corresponding to amino acids 82-256 of the
human SDC-1 core protein. Arrows point to SDC-1 immunoreactive product localized in ductal epithelial cells.
doi:10.1371/journal.pone.0020502.g003
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vitro upregulation of SDC-1 by n-3 PUFA in human breast and
prostate cancer cells as well as in vivo upregulation of SDC-1 in
prostate tissue by an n-3 PUFA-enriched diet [20,21,22,40]. We
have further shown that SDC-1 plays a key role in the anti-tumor
properties of n-3 PUFA through induction of apoptosis via
inhibition of the PDK-1-Akt-Bad signaling pathway [22,48].
In animals fed the n-6 PUFA diet, the similar increase in n-6/n-3
PUFA ratios of lipoproteins between the genotypes indicated that
they directly reflected dietary PUFA intake with little influence of
the fat-1 transgene. Although, dietary effects on plasma lipids are
strongest in the early postprandial period, mice will generally shift
their tissue fatty acid compositions with time on diet to become
morelike the diet.Sincethe mice were fed the diet forseveralweeks,
the differences in postprandial and fasting fatty acid compositions
would be small. Further, the 4 h fasting period should mean that
mostofthepostprandialchylomicronshavebeen cleared sothatat4
h, the effects of any difference in postprandial fatty acid
compositions are minimal. Yet, in spite of similar lipoprotein fatty
acids, the endogenously synthesized n-3 PUFA in the mammary
and liver tissues was sufficient to increase SDC-1 expression. We
have previously shown that DHA delivered by the LDL pathway in
vitro is able to upregulate SDC-1 through activation of PPARc
[21,22]. The results of the present study would be consistent with
activation of PPARc by endogenous n-3 PUFA but in addition raise
the interesting possibility that in vivo, endogenously synthesized-
PUFA and LDL-delivered PUFA may compartmentalize to impact
different pathways of gene regulation. In addition, our study shows
for the first time that n-3PUFA upregulate syndecan-1 inthe mouse
liver, where this proteoglycan plays a primary role in triglyceride–
rich lipoprotein clearance [38]. This suggests that through
syndecan-1, n-3 PUFA may have beneficial effects on lipoprotein
homeostasis relative to cardiovascular disease.
Although there are some conflicting reports [49,50], evidence is
strong for an anti-tumor role for n-3 PUFA, and human trials are
showing promise that DHA combined with chemotherapy may
improve outcome for breast cancer patients [51,52]. However, not
all studies have indicated a tumor inhibitory role for SDC-1 which
appears to be pleiotropic depending on the tissue and cell of origin.
In a variety of epithelial cancers, SDC-1 expression is reduced or
totally lost with tumor progression and aggressive phenotype
[53,54,55,56,57] and low SDC-1 expression was shown to be
associated with poor prognostic outcome and shorter survival
[54,56,58,59,60]. Other studies have shown that in breast,
ovarian, and gastric cancer, the loss in cancer cell SDC-1 is
accompanied by increased stromal SDC-1 expression and adverse
clinical outcome [61,62,63,64]. Clearly the SDC-1 content of a
tissue depends on the combined output of heterogeneous cell
types. In normal mammary tissue, such as in the Fat-1 and wt
mice, adipocytes are a major cell type present (data not shown)
whose contribution to the SDC-1 content is unknown.
Our data indicate upregulation of SDC-1 in the Fat-1 mouse at
the level of both transcription and translation. An additional level
of modification affecting the role of SDC-1 in any tissue relates to
the composition and structure of its glycosaminoglycan (GAG)
chains through which it interacts with multiple ligands to direct
cellular responses. The GAG-bearing ectodomains of SDC-1
undergo physiological shedding as a result of proteolytic cleavage
of their core proteins at a specific plasma membrane proximal site
[65,66]. Shedding results in a pool of soluble SDC-1 that competes
for the same ligands as the membrane-bound co-receptor. The
ectodomains specifically inhibit the in vitro growth of cancer cells
[32,67,68]. However, the inhibitory activity can be reversed by
heparanase that generates fragments of heparan sulfate that
activate fibroblast growth factor-2 [69]. Heparanase is known to
promote progression in a number of cancers [70] and its presence
may be a major determinant on whether SDC-1 plays a tumor-
promoting or tumor inhibitory role [71].
In summary, studies to date indicate a complicated relationship
between SDC-1 and cancer. One direction that may help to
unravel its role in cancer is to examine the regulation of SDC-1 by
tumor suppressive or promoting agents. Our previous studies
strongly supported an upregulation of SDC-1 by n-3 PUFA that
resulted in reduced growth and apoptosis induction in breast
cancer cells in vitro [21,22]. The present study has confirmed in
vivo elevation of SDC-1 in n-3 PUFA-enriched mammary tissues
of the Fat-1 mouse.
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